• 提示：詳情請(qǐng)下載說明書。

• 產(chǎn)品描述： LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor. Phase 1.

• 靶點(diǎn)： Phosphatase

• 體外研究：
  在胰腺癌異種移植小鼠模型中, LB-100（2 mg/kg,i.p.）可增加化療藥物阿霉素的療效.LB-100使腫瘤表面血流速度和腫瘤微血管密度增加

• 體內(nèi)研究：
  與對(duì)照組相比,LB-100使細(xì)胞內(nèi)阿霉素濃度升高約2.5倍,并增加腫瘤細(xì)胞對(duì)阿霉素的敏感性。LB-100使血管內(nèi)皮生長(zhǎng)因子分泌增加,從而促進(jìn)HIF-1α-VEGF介導(dǎo)的血管生成。LB-100對(duì)BxPc-3（IC50：2.3 μM）和Panc-1（IC50：1.7 μM）細(xì)胞的生長(zhǎng)有明顯抑制效果。經(jīng)LB-100處理后,BxPc-3、SW1990和Panc-1細(xì)胞腫的PP2A活性下降30-50%

• 細(xì)胞實(shí)驗(yàn)： Cytotoxicity is conducted by using a Cell Counting Kit-8. Cells are seeded in 96-well plates with a density of 3000 cells per well and are assessed after treatments following the CCK-8 protocol. Relative cytotoxicity is expressed as a percentage of speci?c controls. (Only for Reference)

• 參考文獻(xiàn)：
  1. Bai X, et al. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Lett. 2014 Oct 7. pii: S0304-3835(14)00589-8. 2. Fu QH, et al. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation. Tumour Biol. 2016 Jun;37(6):7277-8 3. Bai XL, et al. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72.

• 溶解性： Soluble  in  H2O

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	3.727 ml	18.635 ml	37.27 ml
  5 mM	0.745 ml	3.727 ml	7.454 ml
  10 mM	0.373 ml	1.864 ml	3.727 ml
  50 mM	0.075 ml	0.373 ml	0.745 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號(hào)：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *